Journal of Pharmacy Practice · 2018 · 10 citations · 5 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDrug InteractionsPharmacovigilanceDrug Interaction ManagementDrug-drug InteractionsInteraction ScreeningPharmacoepidemiologyClinical Drug Interaction Study DesignConcomitant Medication EffectsDirect Oral Anticoagulant InteractionsDirect Oral Anticoagulant SafetyDrug Interactions In AnticoagulationInpatient ScreeningP2y12 Receptor InhibitorsTriple Antiplatelet Therapy
Objective: The aim of this study is to assess patterns of potential drug–drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting. Methods: A retrospective chart review was conducted at the Brookdale University Hospital and Medical Center (BUHMC) from January 2014 to November 2016. All adult patients admitted to the BUHMC who were treated with a DOAC for at least 3 days were screened. Among them, those who received selected interacting drugs at any time during the course of DOAC therapy were included in this study. Results: This study included 165 patients with an average of 73 years (standard deviation [SD] = 12.3) and 233 cases. The most commonly used concomitant drug with a DOAC was aspirin (58%), followed by amiodarone (16%) and P2Y 12 inhibitors (11%). The combined use of dual antiplatelet therapy and a DOAC was identified in 18 (6%) cases. Approximately one-third of the cases encountered were classified as the “avoidance” category. Conclusions: Despite computerized DDI alerts, potentially significant DDIs with DOACs still occur. While the present study provides insight into the current patterns of DDIs, further studies are needed to evaluate clinical outcomes of the potential DDIs with DOACs in practice.
5
Antithrombotic Therapy for VTE Disease
Clive Kearon, Elie A. Akl, Joseph Ornelas et al. · CHEST Journal · 2016 · 4.8K citations
Hein Heidbüchel, Peter Verhamme, Marco Alings et al. · European Heart Journal · 2016 · 269 citations · Full text